ATE.V - Antibe Therapeutics Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.3850
0.0000 (0.00%)
At close: 3:46PM EDT
Stock chart is not supported by your current browser
Previous Close0.3850
Open0.3800
Bid0.3800 x 0
Ask0.3900 x 0
Day's Range0.3750 - 0.3850
52 Week Range0.2350 - 0.4700
Volume327,369
Avg. Volume884,655
Market Cap104.037M
Beta (3Y Monthly)-0.99
PE Ratio (TTM)N/A
EPS (TTM)-0.0600
Earnings DateNov 21, 2019 - Nov 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.40
  • Zacks Small Cap Research

    ATE.V: Phase 2b Efficacy Data Expected in 4Q19…

    In March 2019, Antibe Therapeutics Inc. (ATE.V) announced that the Phase 2b dose-ranging, efficacy study of ATB-346 had commenced. Study subjects will receive once daily doses of placebo or ATB-346 (150 mg, 200 mg, or 250 mg) over a 14-day treatment period. Twelve patients were treated once daily with 250 mg of ATB-346, which is only 1/6th of the typical daily dose of naproxen for treating osteoarthritis.

  • Business Wire

    Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results

    Antibe Therapeutics Inc. filed its financial and operating results on Tuesday, August 27th for the fiscal quarter ended June 30, 2019.

  • Business Wire

    Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346

    Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today provides an update on the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The clinical study commenced in March 2019 and is designed to validate the efficacy of ATB-346 in reducing pain and establish the dose for Phase 3 development. The clinical trial is proceeding well and the Company is pleased with the execution and quality of patient screening, which determines admittance into the study across the 35 clinical sites.

  • Business Wire

    Antibe Announces Closing of Public Offering

    Antibe Therapeutics Inc. (“Antibe” or the “Company”) (ATE.V), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that is has closed its previously announced public offering of 26,833,332 units of the Company (the “Units”) at a price of $0.30 per Unit (the “Offering Price”) for aggregate gross proceeds of $8,050,000 (the “Offering”). The Offering was made pursuant to an amended and restated agency agreement effective August 7, 2019 with a syndicate of agents led by Bloom Burton Securities Inc., together with Echelon Wealth Partners Inc., Dominick Capital Corporation and Industrial Alliance Securities Inc. (collectively, the “Agents”).

  • Business Wire

    Antibe Therapeutics Announces Filing of Final Short Form Prospectus

    Antibe Therapeutics Inc. (“Antibe” or the “Company”) (ATE.V), a leader in developing safer therapeutics for pain and inflammation, announces that it has filed a final short form prospectus (the “Final Prospectus”) relating to the Company’s marketed offering (the “Offering”) of units of the Company (the “Units”). Pursuant to the Final Prospectus, the Offering will be for a minimum of 23,333,333 Units and up to a maximum of 26,833,333 Units for minimum gross proceeds of $7,000,000 and maximum gross proceeds of $8,050,000.

  • CNW Group

    IIROC Trading Resumption - ATE

    IIROC Trading Resumption - ATE

  • CNW Group

    IIROC Trading Halt - ATE

    IIROC Trading Halt - ATE

  • Zacks Small Cap Research

    ATE.V: Results from Phase 2b Efficacy Trial in 3Q19…

    In March 2019, Antibe Therapeutics Inc. (ATE.V) announced that the Phase 2b dose-ranging, efficacy study of ATB-346 had commenced. Study subjects will receive once daily doses of placebo or ATB-346 (150 mg, 200 mg, or 250 mg) over a 14-day treatment period. Twelve patients were treated once daily with 250 mg of ATB-346, which is only 1/6th of the typical daily dose of naproxen for treating osteoarthritis.

  • Business Wire

    Antibe Therapeutics Announces CEO Letter to Shareholders

    As we approach the end of Phase 2 development for ATB-346 and launch into global partnering discussions, we thought this would be an ideal time to reflect on recent developments and reiterate our strategy to maximize value for shareholders. Last year was pivotal for Antibe as we delivered dramatic gastrointestinal (“GI”) safety data for our lead drug, ATB-346, in a head-to-head Phase 2B study versus naproxen, the most prescribed NSAID in the United States. Collectively, this gave us the confidence to march forward with a Phase 2B efficacy study of impressive scale – a total of 360 patients across 35 clinical sites in what is considered one of the largest clinical studies ever undertaken in Canada.

  • Is Antibe Therapeutics Inc.'s (CVE:ATE) CEO Overpaid Relative To Its Peers?
    Simply Wall St.

    Is Antibe Therapeutics Inc.'s (CVE:ATE) CEO Overpaid Relative To Its Peers?

    Dan Legault has been the CEO of Antibe Therapeutics Inc. (CVE:ATE) since 2009. First, this article will compare CEO...

  • Should You Worry About Antibe Therapeutics Inc.'s (CVE:ATE) CEO Salary Level?
    Simply Wall St.

    Should You Worry About Antibe Therapeutics Inc.'s (CVE:ATE) CEO Salary Level?

    Dan Legault became the CEO of Antibe Therapeutics Inc. (CVE:ATE) in 2009. This analysis aims first to contrast CEO...

  • Business Wire

    Antibe Therapeutics Unveils Lead Indication for ATB-352, a Potent, Non-Addictive Analgesic for Severe Pain

    Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the lead indication for its second pipeline drug, ATB-352, a potent and non-addictive analgesic for the treatment of severe pain. The Company will be targeting post-operative pain as the lead indication for ATB-352, a US$9 billion market that is in desperate need of safer and non-addictive therapies. “The availability of safe and effective non-opioid therapies for post-operative pain is limited and represents a clear unmet medical need,” remarked Dan Legault, Antibe’s CEO.

  • Business Wire

    Antibe Therapeutics Announces Upcoming Conference Schedule

    Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce its conference schedule for the upcoming months. Antibe will be engaging in several days of one-on-one meetings with pharmaceutical companies to discuss licensing and partnering opportunities for Antibe’s lead drug, ATB-346. BIO International is the largest biopharma partnering event of the year, attracting over 16,000 leaders and business development executives from 5,000 companies across the globe.

  • Simply Wall St.

    What Kind Of Investor Owns Most Of Antibe Therapeutics Inc. (CVE:ATE)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who really controls Antibe Therapeutics Inc. (CVE:ATE), then you'll have to look...

  • Business Wire

    Antibe Therapeutics to Present at 2019 Bloom Burton & Co. Healthcare Investor Conference

    Antibe Therapeutics Inc. , a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co.

  • Business Wire

    Phase 2B GI Safety Results For ATB-346 Published in British Journal of Pharmacology

    Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today highlights that a research article has been published in the British Journal of Pharmacology (“BJP”) on the successful Phase 2B GI safety trial for its lead drug, ATB-346. BJP is considered one of the world’s pre-eminent scientific journals in pharmacology. “We are pleased that the results of our Phase 2B GI safety study for ATB-346 have been published in BJP,” remarked John Wallace, Antibe’s Chief Scientific Officer.

  • Zacks Small Cap Research

    ATE.V: Phase 2b Efficacy Trial for ATB-346 Underway…

    On March 29, 2019, Antibe Therapeutics Inc. (ATE.V) announced that the Phase 2b dose-ranging, efficacy study of ATB-346 has commenced. Study subjects will receive once daily doses of placebo or ATB-346 (150 mg, 200 mg, or 250 mg) over a 14-day treatment period. In addition to initiating the Phase 2b efficacy study, following the recent financing the company now has sufficient capital to perform key requirements prior to commencing Phase 3 studies of ATB-346, including end-of-Phase 2 FDA meetings, additional pharmacokinetic metabolite studies, and long range (6-month rat and 9-month canine) animal toxicology studies.

  • Business Wire

    Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346

    Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that its Phase 2B dose-ranging, efficacy study for ATB-346 has formally commenced. The study is designed to validate the efficacy of ATB-346 in reducing osteoarthritis (“OA”) pain and establish the dose for Phase 3 development. “We are excited to officially commence the final Phase 2 study for ATB-346,” commented Dan Legault, Antibe’s CEO.

  • Zacks Small Cap Research

    ATE.V: Set to Initiate Phase 2b Efficacy Trial for ATB-346; Completes CAD$5.75 Million Financing…

    On February 15, 2019, Antibe Therapeutics, Inc. (TSX:ATE.V) announced financial results for the third quarter of fiscal year 2019 ending Dec. 31, 2018. The company reported CAD$2.5 million in revenue for the three months ending Dec. 31, 2018 compared to CAD$2.2 million for the three months ending Dec. 31, 2017.

  • Business Wire

    Antibe Therapeutics Inc. Announces Closing of $5.75 Million Bought Deal Offering

    Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that is has closed its previously announced bought deal public offering of 23,000,000 units of the Company (the “Units”) at a price of $0.25 per Unit (the “Offering Price”) for aggregate gross proceeds of $5,750,000 (the “Offering”), including the exercise in full of the Underwriters’ over-allotment option. The Offering was made pursuant to an underwriting agreement dated February 8, 2019 with a syndicate of underwriters led by Bloom Burton Securities Inc., together with Echelon Wealth Partners Inc. and Dominick Capital Corporation (collectively, the “Underwriters”).

  • Business Wire

    Antibe Therapeutics Recognized as a 2019 TSX Venture 50 Company

    Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has been named a 2019 TSX Venture 50™ company, an award that recognizes the top performing companies on the TSX Venture Exchange over the past year. Antibe was ranked second in the Clean Technology and Life Sciences sector. The TSX Venture 50™ is a ranking of the top ten performers on TSX Venture Exchange from each of five industry sectors: Clean Technology and Life Sciences, Diversified Industries, Energy, Mining, and Technology.